Advice
in the absence of a submission from the holder of the marketing authorisation:
vericiguat (Verquvo®) is not recommended for use within NHSScotland.
Indication under review: Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice613KB (PDF)
Medicine details
- Medicine name:
- vericiguat (Verquvo)
- SMC ID:
- SMC2425
- Indication:
For treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 October 2021